ustekinumab biosimilar ABP 654

ABP 654 is a biosimilar to ustekinumab, a recombinant human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that acts as an antagonist of interleukin-12 (IL-12) and interleukin-23 (IL-23). It binds with high specificity and affinity to the p40 protein subunit shared by both IL-12 and IL-23 cytokines, thereby inhibiting their signaling pathways. This mechanism disrupts inflammatory cascades involved in chronic immune-mediated diseases. ABP 654 is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients, active psoriatic arthritis in adults and pediatric patients, moderate-to-severe active Crohn’s disease in adults, and moderate-to-severe active ulcerative colitis in adults. Developed by Amgen, ABP 654 is the first FDA-approved interchangeable biosimilar for ustekinumab[1][2][3][4][5][6].

Brand names

WEZLANAWEZENLA

Other names

ustekinumab-auub